The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from ...
The company saw strong sales from its top-selling cancer drug Keytruda, recently launched treatments and its animal health ...
Keytruda (pembrolizumab) is a prescription drug that’s used to treat certain forms of cancer. Keytruda comes as an intravenous (IV) infusion (an injection into your vein given over time ...
Germany-based BioNTech got into the space before the gold rush that was unleashed in September by the news that Akeso and ...
Keytruda in early-stage triple-negative breast cancer led to immune-related adverse effects, including severe GI issues and ...
Merck's Q3 revenue rises, led by Keytruda's strong 17% YoY growth. Gardasil demand challenges in China impact sales, with ...
IO Biotech (IOBT) announced data from the NSCLC cohort in the company’s Phase 2 basket trial of IO102-IO103, the company’s lead investigational candidate, given in combination with Merck’s anti-PD-1 ...
While Merck's oncology powerhouse Keytruda delivered another multibillion-dollar sales haul in the third quarter, regional ...
Michael Okunewitch, an analyst from Maxim Group, maintained the Buy rating on Citius Pharmaceuticals (CTXR – Research Report). The ...
Hosted on MSN21d
Up Over 600% in 2024, Can Summit Therapeutics Stock Keep Rising?Summit's market cap shot above $23 billion in September after investors saw interim results of the Harmoni-2 trial. The study ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback